KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Jazz Pharmaceuticals (JAZZ) Short-term Investments (2016 - 2017)

Jazz Pharmaceuticals has reported Short-term Investments over the past 4 years, most recently at $200.0 million for Q3 2017.

Quarterly Short-term Investments rose 236.6% to $200.0 million in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $200.0 million through Sep 2017, up 236.6% year-over-year, with the annual reading at $60.0 million for FY2016, N/A changed from the prior year.
Short-term Investments was $200.0 million for Q3 2017 at Jazz Pharmaceuticals, up from $80.0 million in the prior quarter.
Over five years, Short-term Investments peaked at $200.0 million in Q3 2017 and troughed at $764000.0 in Q1 2016.